PostEra

PostEra is a biotechnology company specializing in preclinical drug research using an AI platform.

History

2022: Raising $24 million

In early January 2022, PostEra raised $24 million as part of the Series A investment round. The round was led by Clermont Group with the participation of Breyer Capital, Lifeforce Capital, the Russian I2BF Global Ventures fund Ilya Golubovich, as well as existing investors, including Metaplanet, HOF Capital, Ace & Company, Pioneer Fund and entrepreneur R. Martin Chavez.

Russians have invested in an American AI platform for drug research PostEra

PostEra plans to use the funds raised to promote a series of drug development partnership programs, initiate its own drug development programs and further develop its medical chemistry platform. The company also announced a multi-purpose strategic partnership with Pfizer, within the framework of which, in particular, an artificial intelligence laboratory will be created. PostEra and Pfizer are already working together on several programs to find new drugs with a focus on oncology and antiviral therapy COVID-19. The AI laboratory is expected to use new machine learning for medical chemistry, based on Pfizer data and PostEra innovations in generative chemistry and synthesis-driven design.

We are investing in enterprises aimed at the benefit of society, "said Sean Gardiner, senior vice president of the Clermont Group. - PostEra leads the development of medical chemistry thanks to its advanced artificial intelligence technology. We look forward to working with the team to build an industry-leading drug development platform.

In 2021, PostEra has proven itself well in various programs for the search for new drugs, integrating the development-creation-testing cycle of medical chemistry. For example, the company has achieved results in the rapid development of oral antiviral drugs for COVID.^[1]

Notes